144 related articles for article (PubMed ID: 17683807)
1. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Collado B; Prieto JC; Bajo AM
Regul Pept; 2007 Dec; 144(1-3):101-8. PubMed ID: 17683807
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells.
Collado B; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2006 Apr; 249(1-2):116-22. PubMed ID: 16563610
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
Valdehita A; Bajo AM; Schally AV; Varga JL; Carmena MJ; Prieto JC
Mol Cell Endocrinol; 2009 Apr; 302(1):41-8. PubMed ID: 19101605
[TBL] [Abstract][Full Text] [Related]
4. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.
Valdehita A; Bajo AM; Fernández-Martínez AB; Arenas MI; Vacas E; Valenzuela P; Ruíz-Villaespesa A; Prieto JC; Carmena MJ
Peptides; 2010 Nov; 31(11):2035-45. PubMed ID: 20691743
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells.
Collado B; Gutiérrez-Cañas I; Rodríguez-Henche N; Prieto JC; Carmena MJ
Regul Pept; 2004 Jun; 119(1-2):69-75. PubMed ID: 15093699
[TBL] [Abstract][Full Text] [Related]
7. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Bajo AM; Prieto JC
Mol Cell Endocrinol; 2012 Jan; 348(1):241-6. PubMed ID: 21896307
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro.
Yang J; Shi QD; Song TB; Feng GF; Zang WJ; Zong CH; Chang L
Peptides; 2013 Apr; 42():105-11. PubMed ID: 23340020
[TBL] [Abstract][Full Text] [Related]
9. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Fernández-Martínez AB; Collado B; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2007 May; 270(1-2):8-16. PubMed ID: 17434257
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
13. VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.
Fernández-Martínez AB; Carmena MJ; Bajo AM; Vacas E; Sánchez-Chapado M; Prieto JC
Cell Signal; 2015 Feb; 27(2):236-44. PubMed ID: 25446255
[TBL] [Abstract][Full Text] [Related]
14. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model.
Collado B; Carmena MJ; Clemente C; Prieto JC; Bajo AM
Peptides; 2007 Sep; 28(9):1896-901. PubMed ID: 17544169
[TBL] [Abstract][Full Text] [Related]
17. Chemically modified tetracyclines inhibit VEGF secretion by breast cancer cell lines.
Kothari M; Simon SR
Cytokine; 2006 Aug; 35(3-4):115-25. PubMed ID: 16978872
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP
Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
[TBL] [Abstract][Full Text] [Related]
19. VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis.
Banerjee S; Mehta S; Haque I; Sengupta K; Dhar K; Kambhampati S; Van Veldhuizen PJ; Banerjee SK
Biochemistry; 2008 Mar; 47(11):3345-51. PubMed ID: 18284215
[TBL] [Abstract][Full Text] [Related]
20. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
